Clinical Practice Session
Iron, Erythropoietin, and Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors in CKD and ESKD
October 24, 2024 | 10:30 AM - 12:30 PM
Location: Ballroom 20D, Convention Center
Session Description
Anemia is a frequent complication in patients with kidney diseases. This session discusses iron deficiency anemia, including effects of iron deficiency on nonhematologic organ systems. The pharmacology of various preparations of iron-replenishing agents and erythropoietin-stimulating agents is compared and contrasted. The novel class of agents, hypoxia-inducible factor-prolyl hydroxylase inhibitors, is discussed with suggestions for how to incorporate them into clinical practice.
Learning Objective(s)
- Summarize potential adverse effects of iron deficiency on nonhematologic organ systems
- Distinguish clinically available iron replacement and erythropoietin-stimulating agent formulations
- Appraise the role of hypoxia-inducible factor-prolyl hydroxylase inhibitors in the treatment of anemia in patients with kidney diseases
Learning Pathway(s)
- CKD Non-Dialysis
- Dialysis
Moderators
Presentations
- Nonhematologic Effects of Iron Deficiency
10:30 AM - 11:00 AM
- Which Iron Formulation? And When?
11:00 AM - 11:30 AM
- Are All Erythropoietin-Stimulating Agents the Same?
11:30 AM - 12:00 PM
- Where Do Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors Belong in the Anemia Toolbox?
12:00 PM - 12:30 PM